- Home
- ARQT vs QDEL Comparison
ARQT vs QDEL Comparison
Compare ARQT & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- QDEL
- Stock Information
- Founded
- ARQT 2016
- QDEL 1979
- Country
- ARQT United States
- QDEL United States
- Employees
- ARQT N/A
- QDEL N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- QDEL Medical Specialities
- Sector
- ARQT Health Care
- QDEL Health Care
- Exchange
- ARQT Nasdaq
- QDEL Nasdaq
- Market Cap
- ARQT 2.1B
- QDEL 1.9B
- IPO Year
- ARQT 2020
- QDEL N/A
- Fundamental
- Price
- ARQT $17.71
- QDEL $29.74
- Analyst Decision
- ARQT Strong Buy
- QDEL Buy
- Analyst Count
- ARQT 7
- QDEL 6
- Target Price
- ARQT $19.00
- QDEL $40.17
- AVG Volume (30 Days)
- ARQT 1.6M
- QDEL 1.2M
- Earning Date
- ARQT 11-05-2025
- QDEL 11-06-2025
- Dividend Yield
- ARQT N/A
- QDEL N/A
- EPS Growth
- ARQT N/A
- QDEL N/A
- EPS
- ARQT N/A
- QDEL N/A
- Revenue
- ARQT $263,464,999.00
- QDEL $2,741,600,000.00
- Revenue This Year
- ARQT $72.46
- QDEL N/A
- Revenue Next Year
- ARQT $31.69
- QDEL $3.40
- P/E Ratio
- ARQT N/A
- QDEL N/A
- Revenue Growth
- ARQT 99.50
- QDEL N/A
- 52 Week Low
- ARQT $8.03
- QDEL $22.05
- 52 Week High
- ARQT $18.15
- QDEL $49.45
- Technical
- Relative Strength Index (RSI)
- ARQT 63.97
- QDEL 58.88
- Support Level
- ARQT $16.62
- QDEL $28.41
- Resistance Level
- ARQT $18.15
- QDEL $30.28
- Average True Range (ATR)
- ARQT 0.69
- QDEL 1.32
- MACD
- ARQT 0.03
- QDEL 0.09
- Stochastic Oscillator
- ARQT 85.57
- QDEL 84.44
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.